Appendix 4G

Key to Disclosures Corporate Governance Council Principles and Recommendations

Name of	of entity		
Atomo	Diagnostics Limited		
ABN/AI	RBN		Financial year ended:
37 142	2 925 684		30 June 2023
Our co	rporate governance statem	ent ¹ for the period above can be fo	ound at: ²
	These pages of our annual report:		
\boxtimes	This URL on our website:	https://www.atomodiagnostics.com	m/why-atomo/governance/
	orporate Governance State ed by the Board.	ment is accurate and up to date as	at 24 August 2023 and has been
The an	nexure includes a key to w	here our corporate governance dis	closures can be located.³
Date:		24 August 2023	
Name of authorised officer authorising lodgement:		Maria Clemente, Company Secre	tary

Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period.

Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of Listing Rule 4.10.3.

Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council's recommendations. It also acts as a verification tool for listed entities to confirm that they have met the disclosure requirements of Listing Rule 4.10.3

The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve different purposes and an entity must produce each of them separately.

See notes 4 and 5 below for further instructions on how to complete this form.

¹ "Corporate governance statement" is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period.

² Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable.

³ Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not applicable and just retain the option that is applicable. If you select an option that includes "OR" at the end of the selection and you delete the other options, you can also, if you wish, delete the "OR" at the end of the selection.

ANNEXURE - KEY TO CORPORATE GOVERNANCE DISCLOSURES

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINC	CIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND O	VERSIGHT	
1.1	A listed entity should have and disclose a board charter setting out: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.	and we have disclosed a copy of our board charter at: https://www.atomodiagnostics.com/why-atomo/governance/	 □ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable
1.2	A listed entity should: (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.		set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.3	A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.		□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable
1.4	The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.		□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable

⁴ Tick the box in this column only if you have followed the relevant recommendation in full for the whole of the period above. Where the recommendation has a disclosure obligation attached, you must insert the location where that disclosure has been made, where indicated by the line with "insert location" underneath. If the disclosure in question has been made in your corporate governance statement, you need only insert "our corporate governance statement". If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg "pages 10-12 of our annual report"). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg "www.entityname.com.au/corporate governance/charters/").

⁵ If you have followed all of the Council's recommendations in full for the whole of the period above, you can, if you wish, delete this column from the form and re-format it.

Corpo	rate Governance Council recommendation	Where a box below is ticked, ⁴ we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.5	A listed entity should: (a) have and disclose a diversity policy; (b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and (c) disclose in relation to each reporting period: (1) the measurable objectives set for that period to achieve gender diversity; (2) the entity's progress towards achieving those objectives; and (3) either: (A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined "senior executive" for these purposes); or (B) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "Gender Equality Indicators", as defined in and published under that Act. If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.	and we have disclosed a copy of our diversity policy at: https://www.atomodiagnostics.com/why-atomo/governance/ and we have disclosed the information referred to in paragraph (c) at: Section 1 of our Corporate Governance Statement and if we were included in the S&P / ASX 300 Index at the commencement of the reporting period our measurable objective for achieving gender diversity in the composition of its board of not less than 30% of its directors of each gender within a specified period N/A	set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.6	A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	and we have disclosed the evaluation process referred to in paragraph (a) at: Section 1 of our Corporate Governance Statement and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: Section 1 of our Corporate Governance Statement	 □ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable

Corpo	orate Governance Council recommendation	Where a box below is ticked, ⁴ we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.7	A listed entity should: (a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	and we have disclosed the evaluation process referred to in paragraph (a) at: Section 1 of our Corporate Governance Statement and whether a performance evaluation was undertaken for the reporting period in accordance with that process at: Section 1 of our Corporate Governance Statement	 □ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable

Corporat	te Governance Council recommendation	Where a box below is ticked, 4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIP	LE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD	VALUE	
2.1	The board of a listed entity should: (a) have a nomination committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.	[If the entity complies with paragraph (a):] and we have disclosed a copy of the charter of the committee at: https://www.atomodiagnostics.com/why-atomo/governance/ and the information referred to in paragraphs (4) and (5) at: the Directors' Report of the 2023 Annual Report. [If the entity complies with paragraph (b):] N/A	set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
2.2	A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.	and we have disclosed our board skills matrix at: Section 2 of our Corporate Governance Statement.	□ set out in our Corporate Governance Statement OR □ we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
2.3	 A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, affiliation or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director. 	and we have disclosed the names of the directors considered by the board to be independent directors at: Section 2 of our Corporate Governance Statement. and, where applicable, the information referred to in paragraph (b) at: N/A and the length of service of each director at: Section 2 of our Corporate Governance Statement	set out in our Corporate Governance Statement
2.4	A majority of the board of a listed entity should be independent directors.		□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable
2.5	The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.		□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable
2.6	A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.		set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCII	PLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALL	Y AND RESPONSIBLY	
3.1	A listed entity should articulate and disclose its values.	and we have disclosed our values at: https://www.atomodiagnostics.com/why- atomo/vision_mission_values/_ and in our Code of Conduct https://www.atomodiagnostics.com/why-atomo/governance/_	□ set out in our Corporate Governance Statement
3.2	A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.	and we have disclosed our code of conduct at: https://www.atomodiagnostics.com/why-atomo/governance/	□ set out in our Corporate Governance Statement
3.3	A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.	and we have disclosed our whistleblower policy at: https://www.atomodiagnostics.com/why-atomo/governance/	□ set out in our Corporate Governance Statement
3.4	A listed entity should: (a) have and disclose an anti-bribery and corruption policy; and (b) ensure that the board or committee of the board is informed of any material breaches of that policy.	and we have disclosed our anti-bribery and corruption policy at: https://www.atomodiagnostics.com/why-atomo/governance/	□ set out in our Corporate Governance Statement

Corpora	e Governance Council recommendation	Where a box below is ticked, ⁴ we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIP	LE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPOR	TS	
4.1	The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	[If the entity complies with paragraph (a):] and we have disclosed a copy of the charter of the committee at: https://www.atomodiagnostics.com/why-atomo/governance/ and the information referred to in paragraphs (4) and (5) at: the Directors' Report of the 2023 Annual Report and Section 4 of our Corporate Governance Statement. [If the entity complies with paragraph (b):] and we have disclosed the fact that we do not have an audit committee and the processes we employ that independently verify and safeguard the integrity of our corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner at: N/A	set out in our Corporate Governance Statement
4.2	The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.		□ set out in our Corporate Governance Statement
4.3	A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.		□ set out in our Corporate Governance Statement

		Where a box below is ticked, ⁴ we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIP	LE 5 – MAKE TIMELY AND BALANCED DISCLOSURE		
5.1	A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.	and we have disclosed our continuous disclosure compliance policy at: https://www.atomodiagnostics.com/why-atomo/governance/	□ set out in our Corporate Governance Statement
5.2	A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.		□ set out in our Corporate Governance Statement
5.3	A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.		□ set out in our Corporate Governance Statement
PRINCIP	LE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS		
6.1	A listed entity should provide information about itself and its governance to investors via its website.	and we have disclosed information about us and our governance on our website at: https://www.atomodiagnostics.com/why-atomo/	□ set out in our Corporate Governance Statement
6.2	A listed entity should have an investor relations program that facilitates effective two-way communication with investors.		□ set out in our Corporate Governance Statement
6.3	A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.	and we have disclosed how we facilitate and encourage participation at meetings of security holders at: Section 6 of our Corporate Governance Statement	□ set out in our Corporate Governance Statement
6.4	A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.		□ set out in our Corporate Governance Statement
6.5	A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.		□ set out in our Corporate Governance Statement

Corpora	ate Governance Council recommendation	Where a box below is ticked, ⁴ we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIP	PLE 7 – RECOGNISE AND MANAGE RISK		
7.1	The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework.	[If the entity complies with paragraph (a):] and we have disclosed a copy of the charter of the committee at: https://www.atomodiagnostics.com/why-atomo/governance/ and the information referred to in paragraphs (4) and (5) at: the Directors' Report of the 2023 Annual Report [If the entity complies with paragraph (b):] and we have disclosed the fact that we do not have a risk committee or committees that satisfy (a) and the processes we employ for overseeing our risk management framework at: [insert location]	set out in our Corporate Governance Statement
7.2	The board or a committee of the board should: (a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and (b) disclose, in relation to each reporting period, whether such a review has taken place.	and we have disclosed whether a review of the entity's risk management framework was undertaken during the reporting period at: Section 7 of our Corporate Governance Statement	□ set out in our Corporate Governance Statement

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
7.3	A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.	[If the entity complies with paragraph (a):] and we have disclosed how our internal audit function is structured and what role it performs at: Section 7 of our Corporate Governance Statement [If the entity complies with paragraph (b):] and we have disclosed the fact that we do not have an internal audit function and the processes we employ for evaluating and continually improving the effectiveness of our risk management and internal control processes at: Section 7 of our Corporate Governance Statement	set out in our Corporate Governance Statement
7.4	A listed entity should disclose whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.	and we have disclosed whether we have any material exposure to environmental and social risks at: Section 7 of our Corporate Governance Statement and, if we do, how we manage or intend to manage those risks at: Section 7 of our Corporate Governance Statement	□ set out in our Corporate Governance Statement

Corporate Governance Council recommendation		Where a box below is ticked, ⁴ we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: ⁵
PRINCIP	PLE 8 – REMUNERATE FAIRLY AND RESPONSIBLY		
8.1	The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.	[If the entity complies with paragraph (a):] and we have disclosed a copy of the charter of the committee at: https://www.atomodiagnostics.com/why-atomo/governance/ and the information referred to in paragraphs (4) and (5) at: Section 8 of our Corporate Governance Statement and the Directors' Report of the 2023 Annual Report [If the entity complies with paragraph (b):] N/A	□ set out in our Corporate Governance Statement OR □ we are an externally managed entity and this recommendation is therefore not applicable
8.2	A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	and we have disclosed separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives at: Refer to the Directors' Report in the 2023 Annual Report.	□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable
8.3	A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and (b) disclose that policy or a summary of it.	and we have disclosed our policy on this issue or a summary of it at: Refer to the Directors' Report in the 2023 Annual Report.	 □ set out in our Corporate Governance Statement <u>OR</u> □ we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable





CONTENTS

01.	Foundations for Management and Oversight	3
02.	Structure the Board to be Effective and Add Value	7
03.	A Culture of Acting Lawfully, Ethically and Responsibly	9
04.	Integrity of Corporate Reports	10
05.	Timely and Balanced Disclosure	12
06.	Respecting the Rights of Shareholders	13
07.	Recognising and Managing Risk	14
08.	Remunerate Fairly and Responsibly	16

Atomo Diagnostics Limited (**Atomo** or the **Company**) was admitted to the Official List of the Australian Securities Exchange (**ASX**) on 14 April 2020.

During the financial year ended 30 June 2023, Atomo continued to enhance its governance framework to bring it into alignment with the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations (4th Edition) (**ASX Recommendations**).

This Corporate Governance Statement discloses the extent to which Atomo followed the ASX Recommendations during the reporting period ended 30 June 2023 (**Reporting Period**) and where an ASX Recommendation was not followed for any part of the Reporting Period, states the reasons for not following the Recommendation and any alternative governance practices Atomo adopted in lieu of the Recommendation.

This Corporate Governance Statement has been approved by the Atomo Board and is accurate and up to date as at 24 August 2023 (**Reporting Date**).

This Corporate Governance Statement is available, together with all Charters and Policies referenced in this Statement, on Atomo's website under 'Why Atomo; Governance' at: https://www.atomodiagnostics.com/why-atomo/governance/.



Lay Solid Foundations for Management and Oversight

1.1. Role and Responsibilities of Board and Management

Atomo has a Board Charter setting out the matters expressly reserved to the Board and those delegated to management.

The Board's primary responsibility is to ensure that the Company has an appropriate governance structure to ensure the creation and protection of shareholder value.

Without intending to limit the general role of the Board, the specific principal functions and responsibilities of the Board include:

- a) appointing the Chair;
- delegating appropriate powers to executive Directors and senior
 Management to ensure the effective dayto-day management of the business and monitoring the exercise of these powers;
- appointing, monitoring, replacing and where appropriate removing, senior executives and the Secretary;
- establishing and monitoring executive succession planning;
- e) demonstrating leadership, defining the Company's purpose and setting the Company's strategic direction, objectives and goals; exercising the prudential control of the Company's finances and operations, including monitoring its financial performance and approving its operating budgets and major capital expenditure;
- overseeing the integrity of the Company's accounting and corporate reporting systems, including the external audit;
- g) overseeing senior Management in its implementation of the Company's business model, achievement of the Company's strategic objectives, instilling of the Company's values and performance generally;
- approving the Company's statement of values and code of conduct to underpin the desired culture within the Company;
- ensuring all employees receive appropriate training on the Company's values and senior executives continually referencing and reinforcing those values in their interactions with staff;
- j) ensuring timely, accurate and effective communication with, and reporting to,

- shareholders, the market and relevant regulatory bodies;
- ensuring timely and balanced disclosure of all material information relating to the Company that a reasonable person would expect to have a material effect on the price or value of the Company's securities:
- satisfying itself that the Company has in place an appropriate risk management framework for both financial and nonfinancial risks:
- setting the risk appetite to which the Board expects Management to operate;
- n) approving the Company's remuneration policies and satisfying itself that the Company's remuneration policies are aligned with the Company's purpose, values, strategic objectives and risk appetite;
- evaluating and adopting, with or where appropriate without modification, the ASX Corporate Governance Principles;
- supervising compliance with the Company's corporate governance policies including monitoring the effectiveness of the Company's governance practices;
- q) ensuring that senior Management is effectively reporting to the Board in relation to its duties and activities by having an appropriate framework in place for relevant information to be reported by Management to the Board; and
- placing accountability on Management in relation to the discharge of its duties and challenging them or holding them to account whenever required.

A key component of the Board's governance structure is the delegation of certain responsibilities to its two Board Committees, being the Audit and Risk Committee and People, Culture, Nomination and Remuneration Committee. Each Committee has its own Charter. All Committees, meet at least two times per year and more frequently if required. All Directors have a standing invitation to attend any of the Committee meetings.

The Managing Director is appointed by the Board and is responsible for the ongoing management of the Company in accordance

with the strategy, policies and programs approved by the Board.

The Managing Director's responsibilities include:

- working with the Board to develop a consensus for the Company's vision and direction;
- working with the Company's Management team to construct programs capable of implementing this vision;
- negotiating the terms and conditions of senior executive appointments and presenting them for Board approval;
- d) appointing the senior management team;
- e) endorsing the terms and conditions of appointment of all other staff members;
- f) providing strong leadership to, and effective management of, the Company in order to:
 - i. encourage co-operation and teamwork;
 - ii. build and maintain staff morale; and
 - build and maintain a strong sense of staff identity with, and a sense of allegiance to, the Company;
- g) ensuring a safe workplace for all personnel;
- ensuring a culture of compliance generally, specifically in relation to environmental matters;
- i) carrying out the day-to-day management of the Company;
- j) forming other committees and working parties from time to time as necessary to assist in the orderly conduct and operation of the Company;
- k) keeping the Board adequately informed in 1.4. relation to the activities of the Company; and
- ensuring that all personnel act with the highest degree of ethics and probity.

1.2. Election and Appointment of Directors

Atomo's Board Charter provides that the Board will undertake appropriate checks to determine whether or not to recommend a Director to shareholders for election or re-election or to appoint a Director to fill a casual vacancy. The Charter also confirms the Board's commitment to providing shareholders with all material information in Atomo's possession relevant to a decision on whether or not to elect or re-elect a Director.

As part of Atomo's application for admission to the Official List of ASX in 2020, the Directors of Atomo at that time, provided a national criminal history check obtained from the Australian Federal Police and a search of the Australian National Personal Insolvency Index. In addition, each Director who had in the past 10 years been a resident of a country other than Australia, provided an equivalent national criminal history check and an equivalent national bankruptcy check for each country in which the Director resided.

Atomo arranged for background and criminal record checks to be undertaken prior to the Board's appointment of additional directors and disclosed to security holders all material information in its possession relating to each of the Directors by way of disclosure in its Prospectus and in each notice of general meeting relevant to a decision on whether or not to elect or re-elect a director.

Written Agreement with Directors and Senior Executives

1.3.

Upon appointment, new Directors receive a detailed service agreement which sets out the terms of their appointment, including the required time commitment, remuneration arrangements including superannuation, the requirement to disclose material interests and the requirement to comply with key company policies including Atomo's Code of Conduct.

Senior Executives also receive contracts of employment that set out their terms of employment, including rights and obligations in respect of the termination of their employment and the circumstances in which summary termination may occur.

Appropriate checks are undertaken prior to appointing Senior Executives including criminal record and bankruptcy checks and checks for employment history.

.4. Company Secretary

Atomo's Constitution provides that the Board has reserved to itself the appointment, and removal, of the Company Secretary.

Atomo's Board Charter provides that the Company Secretary is responsible for developing and maintaining the information systems and processes required such that the Board can fulfil its role and is directly accountable to the Board, through the Chair, on all matters relating to the proper functioning of the Board. The Board Charter further provides that the Company Secretary is responsible for overseeing and coordinating disclosure of information to the ASX, as well as communicating with the ASX.

1.5. Diversity

Atomo adopted a Diversity Policy prior to becoming a listed entity. The Policy sets out Atomo's commitment to diversity (including gender, age, ethnicity, disability, family responsibilities, religion and sexual orientation diversity) and creating an inclusive culture in which difference is recognised and valued.

In conjunction with the Diversity Policy, Atomo's Board Charter provides that the composition of the Board must demonstrate an appropriate mix of skills, experience, diversity and knowledge to discharge its responsibilities and objectives.

As at the Reporting Date, Atomo's Board comprises six Directors – five Non-Executive Directors and the Managing Director. Two of Atomo's Non-Executive Directors are female.

The Board has delegated responsibility to the PCNRC for:

- identifying and evaluating the necessary and desirable skills, experience and diversity of the Board and Board Committees;
- developing criteria for the selection of candidates for the Board in light of its desired mix of skills, experience and diversity;
- identifying any deficiencies in the composition of the Board in light of its collective desired mix of skills, experience and diversity;
- making recommendations to the Board on the appointment, re-election and removal of Directors in light of the Board's current skills, experience and diversity; and
- developing a succession plan for the Board with a view to maintaining an appropriate balance of skills, experience and diversity.

The Board is responsible for developing measurable objectives and strategies to meet the objectives of the Diversity Policy. It is also responsible for reviewing annually both the measurable objectives and Atomo's progress in achieving the measurable objectives.

Set out below are the diversity objectives adopted by the Board on 23 March 2021 and Atomo's progress towards achieving the objectives during FY23:

Objective	Progress
Target at least 30% female representation on the Board	Objective continues to be met.
Maintain at least 40%	Objective continues

gender diversity within the workforce.

to be met.

Integrate diversity principles into Atomo's recruitment processes by:

- incorporating a diversity statement on all job advertisements;
- developing selection criteria for internal promotions and external appointments; and
- providing training for all hiring managers on diversity awareness, recognising unconscious bias, inclusive job descriptions and non-discriminatory interview techniques.

Atomo has engaged an external human resources advisor to assist in integrating diversity principles into Atomo's recruitment processes.

Atomo has incorporated a diversity statement into its pro forma job advertisement and has provided training to staff on diversity awareness, recognising unconscious bias and non-discriminatory interview techniques.

Work on the development of selection criteria for internal promotions and external appointments is ongoing.

Undertake a pay equity review to ensure no gender pay bias in remuneration practices and address any gender pay inequity A pay equity review was completed in FY23.

Atomo's workforce diversity as at 30 June 2023 was as follows:

	Female Appointees	% of Women	Male Appointees	% of Men
Director	2	33%	4	67%
Senior Executives	2	50%	2	50%
All Atomo Employees	17	53%	15	47%

1.6. Board Performance Evaluations

Atomo's Board Charter provides that the Company's People, Culture, Nomination and Remuneration Committee (**PCNRC**) will review and evaluate the performance of the Board, individual Directors and Executives on an annual basis.

During FY23, the review process involved:

- a tailored online questionnaire completed by Directors enabling quantitative and qualitative feedback;
- a separate tailored online questionnaire completed pertaining to the performance of the Board Chair;
- a desktop review of key governance documentation; and
- a presentation of the findings to the Board.

The review process aims to ensure that individual Directors continue to contribute effectively to the Board's performance and that the Board as a whole, and its Committees, continue to function effectively.

1.7. **Senior Executive Performance Evaluations**

The Charter of Atomo's PCNRC provides that the Committee will make recommendations to the Board on the criteria for the evaluation of the performance of the senior executive team comprising the Managing Director and the COO and CFO being the Managing Director's direct reports.

During the Reporting Period, the Board evaluated the performance of Atomo's senior executive team against their respective key performance indicators and determined the performance appraisal outcomes for each senior executive.

2. Structure the board to be effective and add value

2.1. Nomination Committee

During FY23, the People, Culture and Remuneration Committee was renamed into the People, Culture, Nomination and Remuneration Committee (**PCNRC**).

In conjunction with this change, the Board Charter was amended to delegate the nomination responsibilities to PCNRC. Under its Charter, the PCNRC continues to have responsibility for monitoring and making recommendations to the Board in relation to:

- the necessary and desirable collective skills, experience and diversity of the Board and Board Committees;
- the independence of each Director, including any potential effect on independence arising out of the directorships held by, or offered to, a Director in other public companies;
- succession plans for the Chair, the Managing Director and direct reports to the Managing Director;
- the Company's induction program for new Directors and ongoing professional development program for Directors; and
- the appointment and re-election of Directors.

2.2. Board Skills Matrix

During FY22, the Board developed a Board Skills Matrix to capture the current mix of skills, competencies and diversity on the Board and to enable the Board to assess whether there are any areas that need to be strengthened in the future having regard to the Company's strategic direction.

During FY23, the Board Skills Matrix was reviewed and updated following a self-assessment questionnaire which required each Director to rate their level of proficiency in each skill area.

The Board considers that the current mix of skills and experience on the Board to be appropriate to the needs of the Company. The collective skills and experience currently on the Board is set out below. The Board will review the Board Skills Matrix annually to ensure that it continues to capture all of the skills, knowledge, experience needed to oversee the Company.

2.3. Director Independence

In assessing the independence of each Director, the Board adopts the factors relevant to assessing Director independence contained in Box 2.3 of the ASX Recommendations. Consistent with the emphasis on 'substance over form' advocated by the ASX Recommendations, Atomo takes a qualitative approach to materiality rather than setting strict quantitative thresholds and considers each Director's individual circumstances on its merits.

The independence of each Director is formally reviewed annually and at any time when a change occurs, that may affect a Director's independence. Non-executive Directors also formally advise the Company Secretary of any relevant information and update the Company Secretary if their circumstances change at any time

In considering the independence of the current Non-executive Directors, the Board considered each Director's tenure and concluded that none have held office for such a period as to compromise their independence. In reaching this conclusion the Board noted that each Director retained independence of character and judgement, and had not formed associations with management (or others, including substantial holders) that might compromise their ability to exercise independent judgement.

The Board considers John Keith, Dr Paul Kasian, Deborah Neff and Dr Cheri Walker to be Independent Non-Executive Directors. John Kelly is the Managing Director and CEO and is therefore not considered to be independent. Dr Curt LaBelle is not considered independent as he is President of Global Health Investment Fund, LLC, a substantial shareholder of Atomo.

The independence and tenure of each member of the current Board is as follows:

Director	Term
John Keith Independent Non-executive Chair	11 Years 9 Months
John Kelly Managing Director and Chief Executive Officer	12 Years 11 Months
Dr Paul Kasian Independent Non-executive Director	3 Years 7 Months

Dr Curt LaBelle Non-executive Director	6 Years 10 Months
Deborah Neff Independent Non-executive Director	1 Year 11 Months
Dr Cheri Walker Independent Non-executive Director	9 Months

2.4. Majority of Independent Directors

The composition of the Board is guided by Atomo's Board Charter which requires that the Board shall be comprised of a majority of independent Non-executive Directors.

At 30 June 2023, the Board comprised six Directors, four of whom were independent Non-executive Directors.

2.5. Independent Chair

John Keith remained Atomo's Chair during the 2023 financial year. Mr Keith was assessed as independent as part of reviews held during the reporting period.

2.6. Director Induction and Education

All new Directors participate in a comprehensive induction program designed to familiarise them with Atomo's business, strategy, operations and Senior Executives. The induction includes a digital Induction Pack containing all relevant corporate governance documents and previous Annual Reports as well as meetings with the Chair of the Board, the CEO, the Board Committee Chairs and each Senior Executive. The new Director also has access to previous Board and Committee minutes.

Ongoing Director education is provided through regular updates on changes in the regulatory environment affecting Atomo and Australian Listed entities. During FY23, it was considered necessary for existing Directors to receive training and briefings on matters including Environmental, Social and Governance Reporting, Cyber Security and Food and Drug Administration regulatory landscape. The training sessions are scheduled to be held before the end of calendar year 2023.

Directors are encouraged to continue their education by attending relevant conferences and seminars and undertaking external education and professional development training.

Instil a culture of acting lawfully, 3. ethically and responsibly

3.1. **Values**

Atomo is committed to making positive economic, social and environmental contributions to each of the communities in which it operates, while complying with all applicable laws and regulations and acting in a manner that is consistent with its values.

Atomo's values, as set out in its Code of Conduct, are:

- Excellence: Being recognised as experts in the field.
- Impact: Commercialising products that matter to our users;
- Innovation: Fostering creative thinking and solutions;
- Integrity: Ensuring honesty and fairness in all that we do.
- Collaboration: Working as one global team: and

Atomo's Code of Conduct requires that the Board be informed immediately of any material non-compliance with the Code.

Management regularly provides assurance reports to the Board in respect of compliance with Atomo's policies and legal obligations.

3.2. **Code of Conduct**

Atomo has adopted a Code of Conduct whose purpose is to provide a framework for decisions and actions by Atomo people. The Code underpins Atomo's commitment to providing professional services and its duty of care to all employees, stakeholders and clients receiving those services.

Staff members are expected to act consistently with the principles set out in the Code of Conduct at all times. Similarly, the Code informs consultants, contractors and partners working with, or for Atomo, of Atomo's values and expectations and their obligation to act in accordance with them.

The Board has adopted this Code to provide a set of guiding principles which are to be observed by all Staff members. This Code has been prepared in accordance with the ASX Recommendations.

3.3. **Whistleblowing Policy**

Atomo recognises whistleblowers play an important role in the identification of wrongdoing and for this reason, they are key players in a company's governance framework, particularly in the area of risk management.

The purpose of Atomo's Whistleblower Policy is

- support the Group's values and Code of Conduct;
- ensure that individuals who disclose wrongdoing can do so safely, securely and with confidence that they will be protected and supported by the Group;
- ensure that whistleblower disclosures are dealt with appropriately and on a timely basis;
- provide transparency regarding the Group's processes for receiving, handling and investigating whistleblower disclosures;
- encourage employees and business partners of the Group to have the confidence to speak up and report wrongdoing; and
- help deter wrongdoing.

A copy of Atomo's Whistleblower Policy is available on its website https://www.atomodiagnostics.com/whyatomo/governance/

Anti-bribery and Corruption Policy 3.4.

Atomo is committed to conducting its business with honesty and integrity at all times and takes a zero-tolerance approach to bribery and corruption.

The purpose of Atomo's Anti Bribery and Corruption (ABC) Policy is to:

- provide clear policies and procedures for employees and other workers in relation to bribery and corruption issues that may arise in the course of their employment;
- provide guidelines for the offering or acceptance of gifts or hospitality;
- assist in the protection of the Company's c) reputation, business and interests;
- d) provide a reporting mechanism for allegations of bribery and corruption; and

e) assist in compliance with legal obligations.

A copy of Atomo's ABC Policy is available on its website

https://www.atomodiagnostics.com/whyatomo/governance/.

4. Safeguard integrity in corporate reporting

4.1. Audit Committee

The Board has established the Audit and Risk Committee (**ARC** or **Committee**) which currently has four members, all of whom are Independent Non-Executive Directors.

Members, Audit and Risk Committee:

Dr Paul Kasian

Chair, Audit and Risk Committee

John Keith

Member, Audit and Risk Committee

Deborah Neff

Member, Audit and Risk Committee

Dr Cheri Walker

Member, Audit and Risk Committee

The ARC has a Charter which can be found on Atomo's website at:

https://www.atomodiagnostics.com/whyatomo/governance/.

Atomo has disclosed in its 2023 Annual Report, the relevant qualifications and experience of the members of the ARC, the number of times the ARC met throughout the Reporting Period and the individual attendances of the members of the ARC at those meetings.

The primary role of the ARC is to monitor and review the effectiveness of the control environment of the Company in the areas of operational and balance sheet risk, legal and regulatory compliance and financial reporting.

The overriding objective of the audit function of the Committee is to provide an independent and objective review of financial and other information prepared by the Company, in particular information that is to be provided to members and/or filed with regulators.

The Committee's responsibilities with respect to its auditing function include:

- a) overseeing the Company's discharge of its responsibilities with respect to:
 - the adequacy of the Company's corporate reporting processes and internal control framework;
 - ii) the extent to which the Company's financial statements, financial reports

- and annual reports reflect the understanding of the Committee members of the Company's financial state of affairs, and provide a true and fair view of the Company's financial position and financial performance;
- iii) the appropriateness of the accounting judgments exercised by management in preparing the Company's financial statements;
- overseeing the Company's relationship with the external audit firm, including their appointment or removal and the fees payable to the audit firm for audit and nonaudit work;
- determining the independence of the external audit firm; and
- d) in respect of the external audit firm, determining the policy for partner rotation.

The Committee will meet and receive regular reports from its external audit firm concerning matters that arise in connection with the Company's audit.

The Committee is also responsible for overseeing the engagement of the external audit firm, including:

- review of the external audit firm's performance;
- the nomination of any new or replacement external audit firm; and
- c) the scope of the external audit firm's work plan. The Committee should also consider any proposal for the external audit firm to provide non-audit services and whether the provision of such services will compromise the independence of the external audit firm

4.2. CEO and CFO Assurance

The Board has adopted policies designed to ensure that Atomo's financial reports:

- are true and fair;
- meet high standards of disclosure and audit integrity; and
- when read with Atomo's other reports to shareholders, provide all material information necessary to understand

Atomo's financial performance and position.

In accordance with section 295A of the Corporations Act for each half and full year financial period the CEO and Managing Director and the CFO provide the Board with a written declaration that, in their respective opinions:

- the financial records of Atomo have been properly maintained in accordance with section 286 of the Corporations Act; and
- the financial statements and notes comply with the accounting standards and present a true and fair view of Atomo's financial condition and performance.

To underpin the integrity of Atomo's financial reporting and Risk Management Framework, it is also Atomo's practice for the CEO and the CFO to state to the Board in writing that, in their respective opinions the statements made regarding the integrity of the financial

statements are founded on a sound system of risk management and internal controls which are operating effectively.

4.3. Integrity of unaudited disclosures

For periodic corporate reports released to the market which are not required to be audited or reviewed by the Company's external auditor, Atomo has a robust verification, review and approval process to ensure the integrity of the information disclosed to the market.

The process involves the reports being prepared and reviewed by relevant subject matter experts, an internal verification and sign off process, material statements reviewed for accuracy, and an appropriate approval process involving senior executives, the CEO, and for disclosure of certain matters which are within the Atomo Board's reserved powers or matters that are otherwise of significance to Atomo, the approval of the Atomo Board.



ACN 142 925 684

5. Make timely and balanced disclosures

5.1. Continuous Disclosure Policy

Atomo has a Continuous Disclosure Policy which sets out the procedures that apply to the central collection, control, assessment and if required, release to the ASX, of information which may affect the price or value of Atomo securities or influence decisions taken by investors to buy or sell Atomo securities.

As a standing agenda item at each Board meeting, Atomo's Directors consider whether or not there is any information (including any matters reported to or discussed at the Board meeting) that may potentially need to be disclosed to the market pursuant to Atomo's continuous disclosure obligations.

5.2. Announcements sent to Directors

All Atomo Directors receive automatic email notification when Atomo releases market announcements including material market announcements.

5.3. Investor Presentations

All investor and analyst presentations given by Atomo are lodged with the ASX ahead of the presentation.

Market briefings, investor presentations and other significant information are made publicly available on Atomo website as soon as it is disclosed to the market.



6. Respect the rights of security holders

6.1. Corporate Information

Atomo is committed to communicating effectively with investors and providing balanced and understandable information about itself and its corporate proposals to the market

Atomo's website includes copies of announcements lodged with the ASX, advance notification of scheduled analyst and media briefings and annual reports.

The Board is committed to giving all shareholders timely and equal access to information to enable them to exercise their rights as investors effectively.

In addition, Atomo publishes a 'Meetings & Reporting Calendar' on its website which sets out the date for the Annual General Meeting (AGM) and key dates for financial lodgement.

6.2. Investor Relations Program

Atomo's investor relations program is designed to engage with its key stakeholders including retail shareholders, institutional investors (domestically and internationally), buy-side and sell-side research analysts and individual investors. The program includes scheduled engagements following the release of its quarterly reports, half and full year results, as well as other engagements including presenting at/or attending industry conferences, strategy and operational updates.

The Board understands the importance of these interactions as it allows Atomo to clearly articulate its strategy and receive feedback from investors and investment market participants on its strategy, financial performance and reporting, and governance.

Key information released and available via the 'Investor Centre' include:

- Quarterly Reports
- Financial Statements for the half and full year results;
- Annual Report;
- Chair's and CEO's addresses to the AGM;
- Corporate Governance Statement;
- market briefings and other significant information; and
- ASX announcements.

Atomo has a Shareholder Communication Policy which sets out Atomo's shareholder communication processes.

Investors are able to contact Atomo or submit questions or comments to Atomo via the 'Contact us' page on Atomo's website, or via a specific email address Atomo has created for investor enquiries

(investorqueries@atomodiagnostics.com).
Additionally, all Atomo ASX announcements provide contact details to facilitate communication with investors.

6.3. Shareholder Engagement at the AGM

The Board promotes shareholder engagement and encourages their participation at Atomo's AGM. Engagement is facilitated by:

- distributing a copy of the annual report and the notice of meeting to shareholders directly via their nominated means of communication;
- enabling the use of online proxy voting for shareholders who are unable to attend;
- encouraging shareholders to submit written questions in advance of the AGM. The Chair of the Board seeks to address as many of the more frequently raised topics as possible in his AGM address; and
- seeking to answer all questions raised by shareholders during the meeting.

The formal addresses at the AGM are lodged on the ASX at least an hour prior to the AGM and shared via a webcast for those shareholders who are unable to attend. A representative of the external auditor, BDO, attends the AGM for the purpose of answering shareholder questions about the audit report and audit process.

For the 2023 AGM, Atomo intends to conduct a physical meeting.

6.4. Use of a Poll at the AGM

All substantive resolutions being considered at the AGM are decided by a poll rather than a show of hands. The AGM voting result is lodged with the ASX as soon as practicable after the AGM and published on Atomo's website.

6.5. Electronic Communications

Atomo security holders have the option to receive communications from, and send communications to Atomo and its security registry, Link Market Services Limited, electronically. Atomo's share registry, Link Market Services Limited, also receives and sends electronic communications to shareholders.

7. Recognising and Managing Risk

7.1. Risk Committee

The ARC is responsible for overseeing and managing risk. The ARC is responsible for the review of the Company's risk management program. It must ensure that areas of key risk (both financial and non-financial) have been identified, and that the appropriate internal controls have been implemented and are operating efficiently in all material respects.

The Committee's responsibilities with respect to its risk identification and management function include:

- a) ensuring legal and regulatory compliance;
- b) ensuring protection of capital;
- implementing and reviewing appropriate risk management systems, the risk appetite statement and the risk management framework to manage both financial and non-financial risks;
- d) monitoring the performance of management against the risk management framework, including whether it is operating within the risk management appetite set by the Board;
- review any material incident involving fraud or a break-down of the Company's risk controls and the "lessons learned";
- receive reports from management on new and emerging sources of risk and the risk controls and mitigation measures that management has put in place to deal with those risks; and
- g) oversee the Company's insurance program, having regard to the Company's business and the insurable risks associated with its business.

Details of the number of meetings held by the ARC and attendance by committee members is set out in Atomo's 2023 Directors' Report.

7.2. Risk Management Framework

During the Reporting Period, the ARC and the Board reviewed Atomo's risk management framework to satisfy themselves that it continues to be sound and that the Company is operating with due regard to the risk appetite set by the Board.

The ARC is responsible for reviewing the Board's risk appetite statement and the risk management framework at least annually.

Management is required to provide an assurance report to the Board at each scheduled Board meeting which includes

confirmation that Atomo's risk management framework is functioning effectively including dealing adequately with contemporary and emerging risks and that all Atomo personnel are operating in compliance with this framework.

7.3. Internal Audit Function

Atomo does not have an internal audit function.

The ARC is responsible for monitoring the effectiveness of Atomo's risk management framework and system of internal control, including making regular requests, receipt and review of reports on material risks and the operation of the Company's internal controls to mitigate those risks.

The Board has delegated to the ARC responsibility for discussing with management and the external audit firm any major issues relating to Atomo's system of internal controls over financial information.

7.4. Material Exposure to Environmental and Social Risks

The Group's operations are not subject to any significant environmental regulation under Australian Commonwealth or State law.

The Company has identified the following sustainability issues most material to its business and are important to key stakeholders such as investors, consumers, customers, supplier, governments and employees.

- Employee health and safety: Ensuring our employees work in a safe environment, which meets or exceeds relevant regulatory expectations, addresses health and safety concerns as they arise and mitigates the risk of reoccurrence of incidents.
- Product quality and safety: Choosing materials from quality sources, complying with ISO 13485 Medical Devices Quality Management, and delivering safe products to customers. Atomo aims to adhere to or exceed strict regulatory standards in all jurisdictions that it serves, and investigates all concerns to ensure our products maintain the highest quality.
- Ethical purchasing and human rights in the supply chain: Responsibility to partners to ensure our product line is free from human rights concerns such as forced labour and trafficking, unsafe labour standards and unfair treatment. These issues can arise wherever human

- resources are utilised across the supply chain.
- Corruption and bribery: Business must be conducted with transparency, and free from unethical persuasion. Ethical business practices relate to every aspect of Atomo's business, from identifying product sources, through the development of diagnostics, transactions with regulatory bodies and sale to customers.
- Compliance: Responsibility to drive compliance with legal and regulatory requirements applicable to our global business. Includes development of policies and controls, communication and training, oversight and continuous improvement and striving for best practice. Consequently, compliance affects every aspect of what we do, to deliver quality products to consumers.
- Resource use and waste management:
 Includes energy usage during manufacture and logistics, water usage and waste as a by-product of manufacture. Stakeholders increasingly demand disclosure of resource usage and waste management for a more sustainable product investment.
- Product pricing and accessibility: Strategies and initiatives designed to provide more affordable diagnostic pricing and accessibility to products for patients through development, manufacture and marketing of high-quality generic and branded products, with a particular focus on accessible diagnostics for the global health and Lower and Middle Income markets.

The Board believes that the Group has adequate systems in place for the management of its exposure to environmental and social risks.

8. Remunerate fairly and responsibly

8.1. Remuneration Committee

The Board has established the PCNRC which comprises three non-executive directors who are considered by the Board to be independent – Deborah Neff, Paul Kasian and John Keith (Chair of the Board). Ms Neff is the Chair of the Committee.

The Committee has a Charter which can be found on Atomo's website at: https://www.atomodiagnostics.com/why-atomo/governance/.

Atomo has disclosed in its 2023 Annual Report, the members of the Committee and the number of times the Committee met throughout the Reporting Period and the individual attendances of the members of the Committee at those meetings.

There are three members of the PCNRC, all of whom are Independent Non-Executive Directors.

Members, People, Culture, Nomination and Remuneration Committee:

Deborah Neff

Chair, People, Culture, Nomination and Remuneration Committee

John Keith

Member, People, Culture, Nomination and Remuneration Committee

Dr Paul Kasian

Member, People, Culture, Nomination and Remuneration

Atomo has disclosed in its 2023 Annual Report, the relevant qualifications and experience of the members of the PCNRC, the number of times the PCNRC met throughout the Reporting Period and the individual attendances of the members of the ARC at those meetings.

The overriding objective of the Committee is to provide an independent and objective perspective on the value and structure of remuneration for each of the Company's Non-Executive Directors, Executive Directors, the Company Secretary, and direct reports to the Managing Director (or equivalent), and other employees, so as to maximise the benefit derived from their skills and experience, promote and sustain a culture aligned with the Company's values and facilitate the long-term growth and success of the Company.

The PCNRC will monitor and make recommendations to the Board in relation to:

Remuneration

- a) the Company's remuneration (including incentives and rewards), recruitment, retention and termination policies and practices for Executive Directors and direct reports to the Managing Director and the alignment of the policies and practices with the promotion and sustainment of a culture aligned with Atomo's values, the promotion of long-term sustainable success and the achievement of the Company's business objectives;
- the remuneration of the Company's nonexecutive directors and the quantum and allocation of the non-executive directors' fee pool;
- c) the administration and operation of the Company's incentive plans; any proposed new incentive plan or change to an existing incentive plan; the proposed issue of invitations under the Company's incentive plans; and the testing of vesting conditions and award of incentives; and
- d) minimum shareholding rules for the Company's directors and executives;
- specific superannuation or retirement arrangements for Executive Directors and direct reports to the Managing Director;
- f) independent, market-based remuneration benchmarks on an annual basis to ensure competitive levels of benefit;
- g) any gender or other inappropriate bias in remuneration for Executive Directors and direct reports to the Managing Director;

People

- h) people strategies and practices which will instil and reinforce the Company's purpose and values, ensure health and wellbeing (physical and mental) and support the achievement of the Company's long-term business objectives;
- the development of, and progress in meeting, the Company's diversity objectives;

Performance

- the Company's performance appraisal processes for the direct reports to the Managing Director and in consultation with the Chair, the performance appraisal process for the Managing Director;
- k) the Company's performance appraisal processes for the Board, Board Committees and individual Non-Executive Directors;

Board Skills

the necessary and desirable collective skills, experience and diversity of the Board and Board Committees;

- m) the independence of each Director, including any potential effect on independence arising out of the directorships held by, or offered to, each Director in other public companies;
- succession plans for the Chair, the Managing Director and direct reports to the Managing Director;
- the Company's induction program for new Directors and ongoing professional development program for Directors;
- p) the re-election of Directors;
- any proposed separation arrangements in respect of the Managing Director or any direct report to the Managing Director; and

Reporting

 the Company's disclosures in relation to people, culture and remuneration matters including those made in the Company's annual remuneration report and annual corporate governance statement.

8.2. Remuneration Policies

Atomo has disclosed in its 2023 Annual Report its policies and practices regarding the remuneration of Non-Executive Directors and the remuneration of the Managing Director and other senior executives.

8.3. Share Trading Policy

Atomo's Share Trading Policy (STP) prohibits Key Management Personnel and their closely related parties who participate in an equitybased employee incentive plan from entering into any transaction which would have the effect of hedging or otherwise transferring to any other person the risk of any fluctuation in the value of any unvested entitlements granted under the plan.

Atomo is committed to complying with the Corporations Act and the ASX Listing Rules to create a transparent market in the trading of its securities on the ASX.

The purpose of Atomo's STP is to ensure all Key Management Personnel and employees are aware of the legal restrictions on trading securities, while in possession of unpublished price sensitive information concerning Atomo.

The objectives of the STP is to:

- minimise the risk of Atomo Personnel contravening the laws against insider trading;
- minimise the risk of the appearance of insider trading and the significant reputational damage that may cause to Atomo:
- ensure Atomo is able to meet its reporting obligations under the ASX Listing Rules; and
- d) increase transparency with respect to trading in Atomo securities by Atomo Personnel.

A copy of Atomo's STP is available on its website

https://www.atomodiagnostics.com/whyatomo/governance/.